Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

GDF11 induces mild hepatic fibrosis independent of metabolic health

J. Frohlich, K. Kovacovicova, T. Mazza, MR. Emma, D. Cabibi, M. Foti, C. Sobolewski, JA. Oben, M. Peyrou, F. Villarroya, M. Soresi, R. Rezzani, M. Cervello, F. Bonomini, A. Alisi, M. Vinciguerra

. 2020 ; 12 (20) : 20024-20046. [pub] 20201028

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019945

BACKGROUND & AIMS: Growth Differentiation Factor 11 (GDF11) is an anti-aging factor, yet its role in liver diseases is not established. We evaluated the role of GDF11 in healthy conditions and in the transition from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). RESULTS: GDF11 mRNA levels positively correlated with NAFLD activity score and with CPT1, SREBP, PPARγ and Col1A1 mRNA levels, and associated to portal fibrosis, in morbidly obese patients with NAFLD/NASH. GDF11-treated mice showed mildly exacerbated hepatic collagen deposition, accompanied by weight loss and without changes in liver steatosis or inflammation. GDF11 triggered ALK5-dependent SMAD2/3 nuclear translocation and the pro-fibrogenic activation of HSC. CONCLUSIONS: GDF11 supplementation promotes mild liver fibrosis. Even considering its beneficial metabolic effects, caution should be taken when considering therapeutics that regulate GDF11. METHODS: We analyzed liver biopsies from a cohort of 33 morbidly obese adults with NAFLD/NASH. We determined the correlations in mRNA expression levels between GDF11 and genes involved in NAFLD-to-NASH progression and with pathological features. We also exposed wild type or obese mice with NAFLD to recombinant GDF11 by daily intra-peritoneal injection and monitor the hepatic pathological changes. Finally, we analyzed GDF11-activated signaling pathways in hepatic stellate cells (HSC).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019945
003      
CZ-PrNML
005      
20210830101542.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/aging.104182 $2 doi
035    __
$a (PubMed)33126224
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Frohlich, Jan $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic
245    10
$a GDF11 induces mild hepatic fibrosis independent of metabolic health / $c J. Frohlich, K. Kovacovicova, T. Mazza, MR. Emma, D. Cabibi, M. Foti, C. Sobolewski, JA. Oben, M. Peyrou, F. Villarroya, M. Soresi, R. Rezzani, M. Cervello, F. Bonomini, A. Alisi, M. Vinciguerra
520    9_
$a BACKGROUND & AIMS: Growth Differentiation Factor 11 (GDF11) is an anti-aging factor, yet its role in liver diseases is not established. We evaluated the role of GDF11 in healthy conditions and in the transition from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). RESULTS: GDF11 mRNA levels positively correlated with NAFLD activity score and with CPT1, SREBP, PPARγ and Col1A1 mRNA levels, and associated to portal fibrosis, in morbidly obese patients with NAFLD/NASH. GDF11-treated mice showed mildly exacerbated hepatic collagen deposition, accompanied by weight loss and without changes in liver steatosis or inflammation. GDF11 triggered ALK5-dependent SMAD2/3 nuclear translocation and the pro-fibrogenic activation of HSC. CONCLUSIONS: GDF11 supplementation promotes mild liver fibrosis. Even considering its beneficial metabolic effects, caution should be taken when considering therapeutics that regulate GDF11. METHODS: We analyzed liver biopsies from a cohort of 33 morbidly obese adults with NAFLD/NASH. We determined the correlations in mRNA expression levels between GDF11 and genes involved in NAFLD-to-NASH progression and with pathological features. We also exposed wild type or obese mice with NAFLD to recombinant GDF11 by daily intra-peritoneal injection and monitor the hepatic pathological changes. Finally, we analyzed GDF11-activated signaling pathways in hepatic stellate cells (HSC).
650    _2
$a dospělí $7 D000328
650    _2
$a zvířata $7 D000818
650    _2
$a kostní morfogenetické proteiny $x genetika $x metabolismus $x toxicita $7 D019485
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a buněčné linie $7 D002460
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a růstové diferenciační faktory $x genetika $x metabolismus $x toxicita $7 D055412
650    _2
$a jaterní hvězdicovité buňky $x metabolismus $x patologie $7 D055166
650    _2
$a lidé $7 D006801
650    _2
$a játra $x metabolismus $x patologie $7 D008099
650    _2
$a jaterní cirhóza $x diagnóza $x etiologie $x genetika $x metabolismus $7 D008103
650    _2
$a experimentální cirhóza jater $x chemicky indukované $x metabolismus $x patologie $7 D008106
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nealkoholová steatóza jater $x diagnóza $x etiologie $x genetika $x metabolismus $7 D065626
650    _2
$a morbidní obezita $x komplikace $x diagnóza $7 D009767
650    _2
$a signální transdukce $7 D015398
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kovacovicova, Kristina $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Mazza, Tommaso $u Bioinformatics Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
700    1_
$a Emma, Maria R $u Institute for Biomedical Research and Innovation, National Research Council (CNR), Palermo, Italy
700    1_
$a Cabibi, Daniela $u Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy
700    1_
$a Foti, Michelangelo $u Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
700    1_
$a Sobolewski, Cyril $u Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland
700    1_
$a Oben, Jude A $u Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL), London, United Kingdom
700    1_
$a Peyrou, Marion $u Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine of the University of Barcelona, Barcelona, Catalonia, Spain $u Institut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain
700    1_
$a Villarroya, Francesc $u Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine of the University of Barcelona, Barcelona, Catalonia, Spain $u Institut de Recerca Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain $u CIBER Fisiopatología de la Obesidad y Nutrición, Barcelona, Catalonia, Spain
700    1_
$a Soresi, Maurizio $u Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy
700    1_
$a Rezzani, Rita $u Anatomy and Physiopathology Division, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy $u Interdepartmental University Center of Research "Adaption and Regeneration of Tissues and Organs-(ARTO)", University of Brescia, Brescia, Italy
700    1_
$a Cervello, Melchiorre $u Institute for Biomedical Research and Innovation, National Research Council (CNR), Palermo, Italy
700    1_
$a Bonomini, Francesca $u Anatomy and Physiopathology Division, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy $u Interdepartmental University Center of Research "Adaption and Regeneration of Tissues and Organs-(ARTO)", University of Brescia, Brescia, Italy
700    1_
$a Alisi, Anna $u Research Area for Multifactorial Diseases, Research Unit of Molecular Genetics of Complex Phenotypes, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
700    1_
$a Vinciguerra, Manlio $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic $u Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL), London, United Kingdom
773    0_
$w MED00172417 $t Aging $x 1945-4589 $g Roč. 12, č. 20 (2020), s. 20024-20046
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33126224 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101542 $b ABA008
999    __
$a ok $b bmc $g 1690695 $s 1140391
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 20 $d 20024-20046 $e 20201028 $i 1945-4589 $m Aging (Albany, NY. Online) $n Aging $x MED00172417
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace